TNXP — Tonix Pharmaceuticals Holding Share News
0.000.00%
Last trade - 00:00- $88.67m
- -$87.56m
- $13.11m
Brief: Tonix Pharmaceuticals Presented Data And Analyses Of Tnx-102
Tonix Pharmaceuticals Holding Corp expected to post a loss of $3.27 a share - Earnings Preview
Tonix Pharmaceuticals Holding Corp expected to post a loss of $3.27 a share - Earnings Preview
Brief: Tonix Pharmaceuticals May Sell Shares Worth Up To $50 Mln
Brief: Tonix Pharmaceuticals Expects About $50 Mln Non-Cash Impairment For Quarter Ended June 30, 2024
Brief: Tonix Pharma- Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
Brief: Tonix Pharmaceuticals Announces Closing Of $4.0 Million Public Offering
Brief: Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
Tonix Pharmaceuticals falls after company announces proposed public offering
Brief: Tonix Pharmaceuticals Announces Proposed Public Offering
Brief: Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting With FDA For Tonmya™ For The Management Of Fibromyalgia
Brief: Tonix Pharmaceuticals Awarded $34 Mln US Department Of Defense Contract For Accelerated Development Of Broad-Spectrum Antiviral Program
Brief: Tonix Pharmaceuticals Entered Into Other Transaction Agreement With Defense Threat Reduction Agency
Brief: Tonix Pharmaceuticals Announces Closing Of $4.0 Million Public Offering
Brief: Tonix Pharmaceuticals Announces Pricing Of Approximately $4.0 Million Public Offering
Brief: L1 Capital Global Opportunities Master Fund, Ltd Reports Passive Stake Of 9.99% In Tonix Pharmaceuticals Holding Corp. As Of June 12 2024- SEC Filing
Brief: Tonix Pharmaceuticals Announces Positive Pre-NDA Meeting With FDA For Tonmya For The Management Of Fibromyalgia
Brief: Tonix Pharmaceuticals Announces Closing Of $4.0 Million Public Offering
Brief: Tonix Pharmaceuticals Announces Pricing Of $4.0 Million Public Offering